ArticleRomanian journal of ophthalmology
Hyaluronic Acid Dermal Filler for Inducing Mechanical Ptosis in Facial Nerve Palsy: A Novel Approach to Treat Exposure Keratopathy.
Article in Romanian journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Beyond reconstruction: minimally invasive aesthetic and regenerative medicine in postoperative oral and maxillofacial surgery.Oral and maxillofacial surgery · 2026Review
- Aesthetic Rehabilitation of Patients with Central and Peripheral Facial Palsy with Injectables (BNT-A, HA-Fillers and CaHa).Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to assess a dermal filler's safety, efficacy, and outcome for inducing temporary mechanical ptosis of the upper eyelid in patients with facial nerve palsy with exposure keratopathy. Methods: A prospective interventional study was conducted on 13 patients with facial nerve palsy with various levels of lagophthalmos and exposure keratopathy. A total of 0.3 ml of dermal filler (Juvéderm Ultra Plus XC, Allergan, USA) was injected subdermally over the pretarsus area of the upper lid to induce mechanical ptosis. Post-dermal filler implantation patients were followed up for a reduction in the amount of lagophthalmos and adverse effects. Results: Out of 13 patients exposed to keratopathy due to facial nerve palsy, two were females, and eleven were males, with a mean age of 54+/-6.5 years and House Brackmann severity grades IV and V. The preinjection average lagophthalmos was 5.5 mm, and it decreased to an average of 0.8 mm postinjection at 1 week of follow-up, which was maintained at 12 weeks and 24 weeks of follow-up. No adverse side effects were observed during the 24-week follow-up.Discussion: This study highlights the effectiveness and safety of hyaluronic acid-based dermal fillers in treating lagophthalmos and exposure keratopathy caused by facial nerve palsy. A single 0.3 ml injection in the pretarsal region successfully induced mechanical ptosis, significantly reducing lagophthalmos and protecting the cornea, with results sustained for 24 weeks and no adverse effects. Offering a minimally invasive, cost-effective alternative to traditional surgical methods, dermal fillers show promise, particularly in early-stage management. Despite a small sample size and limited follow-up, these findings pave the way for future research to refine dosing and assess long-term efficacy. Conclusions: Absorbable dermal filler implants are an easy and effective method for inducing mechanical ptosis and protecting the cornea in patients with exposure keratopathy due to facial nerve palsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.